Cargando…
Methods and Designs of Modern Breast Cancer Confirmatory Trials
SIMPLE SUMMARY: The benefit–risk assessments of new drugs for breast cancer (BC) face several challenges, as all stakeholders do not agree on the evidence bar required for market authorization, and by the fragmentation of breast cancer diagnosis. In this study, we describe the methods and designs of...
Autores principales: | Péron, Julien, Reverdy, Thibaut, Smenteck, Colette, Cortet, Marion, You, Benoît, Freyer, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199547/ https://www.ncbi.nlm.nih.gov/pubmed/34199352 http://dx.doi.org/10.3390/cancers13112757 |
Ejemplares similares
-
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
por: Varnier, Romain, et al.
Publicado: (2021) -
Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020) -
HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023) -
PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022) -
Group sequential and confirmatory adaptive designs in clinical trials
por: Wassmer, Gernot, et al.
Publicado: (2016)